Functional Neurological Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major functional neurological disorder markets reached a value of US$ 10.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.53% during 2024-2034.
The functional neurological disorder market has been comprehensively analyzed in IMARC's new report titled "Functional Neurological Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Functional neurological disorder refers to a complex and multifactorial condition that affects the functioning of the nervous system. The disease can lead to a disconnect between the brain and the body, resulting in several physical signs that can be distressing and debilitating. The symptoms of this ailment can vary widely and may affect various processes related to the body, such as motor, sensory, and cognitive functions. Some common indications associated with the disease include weakness or paralysis of limbs, tremors, irregular movements, gait abnormalities, trouble with attention, concentration, or coordination, memory issues, chronic pain, confusion, numbness, tingling, or loss of feeling in the affected region, vision problems, etc. The diagnosis of this condition mainly relies on the identification of certain clinical features that distinguish it from organic neurological disorders, such as the inconsistency of symptoms, incongruity with known neurological patterns, presence of psychological factors, etc. Additionally, a healthcare professional may perform numerous imaging studies, like magnetic resonance imaging (MRI) or computed tomography (CT) scans, to rule out structural abnormalities or various other organic causes of the indications.
The increasing prevalence of dysfunctions in the neural networks, which can lead to alterations in brain activity and connectivity patterns, is primarily driving the functional neurological disorder market. In addition to this, the rising incidence of psychological trauma, such as sexual or physical abuse, that affects the processing and interpretation of sensory information within the brain is also creating a positive outlook for the market. Moreover, the widespread adoption of mind-body therapies, which involve relaxation exercises, meditation, mindfulness, and yoga to minimize stress and improve overall well-being, is further bolstering the market growth. Apart from this, the inflating application of selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, escitalopram, etc., owing to their several advantages, like reducing disease symptoms and enhancing the brain's adaptive responses, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cognitive-behavioral therapy, which helps to identify and challenge negative or distorted thinking patterns, thereby decreasing emotional distress in individuals suffering from the ailment, is expected to drive the functional neurological disorder market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the functional neurological disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for functional neurological disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the functional neurological disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the functional neurological disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the functional neurological disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current functional neurological disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the functional neurological disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the functional neurological disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the functional neurological disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of functional neurological disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of functional neurological disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of functional neurological disorder by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with functional neurological disorder across the seven major markets?
What is the size of the functional neurological disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of functional neurological disorder?
What will be the growth rate of patients across the seven major markets?
Functional Neurological Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for functional neurological disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the functional neurological disorder market?
What are the key regulatory events related to the functional neurological disorder market?
What is the structure of clinical trial landscape by status related to the functional neurological disorder market?
What is the structure of clinical trial landscape by phase related to the functional neurological disorder market?
What is the structure of clinical trial landscape by route of administration related to the functional neurological disorder market?
The functional neurological disorder market has been comprehensively analyzed in IMARC's new report titled "Functional Neurological Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Functional neurological disorder refers to a complex and multifactorial condition that affects the functioning of the nervous system. The disease can lead to a disconnect between the brain and the body, resulting in several physical signs that can be distressing and debilitating. The symptoms of this ailment can vary widely and may affect various processes related to the body, such as motor, sensory, and cognitive functions. Some common indications associated with the disease include weakness or paralysis of limbs, tremors, irregular movements, gait abnormalities, trouble with attention, concentration, or coordination, memory issues, chronic pain, confusion, numbness, tingling, or loss of feeling in the affected region, vision problems, etc. The diagnosis of this condition mainly relies on the identification of certain clinical features that distinguish it from organic neurological disorders, such as the inconsistency of symptoms, incongruity with known neurological patterns, presence of psychological factors, etc. Additionally, a healthcare professional may perform numerous imaging studies, like magnetic resonance imaging (MRI) or computed tomography (CT) scans, to rule out structural abnormalities or various other organic causes of the indications.
The increasing prevalence of dysfunctions in the neural networks, which can lead to alterations in brain activity and connectivity patterns, is primarily driving the functional neurological disorder market. In addition to this, the rising incidence of psychological trauma, such as sexual or physical abuse, that affects the processing and interpretation of sensory information within the brain is also creating a positive outlook for the market. Moreover, the widespread adoption of mind-body therapies, which involve relaxation exercises, meditation, mindfulness, and yoga to minimize stress and improve overall well-being, is further bolstering the market growth. Apart from this, the inflating application of selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, escitalopram, etc., owing to their several advantages, like reducing disease symptoms and enhancing the brain's adaptive responses, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cognitive-behavioral therapy, which helps to identify and challenge negative or distorted thinking patterns, thereby decreasing emotional distress in individuals suffering from the ailment, is expected to drive the functional neurological disorder market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the functional neurological disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for functional neurological disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the functional neurological disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the functional neurological disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the functional neurological disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current functional neurological disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the functional neurological disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the functional neurological disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the functional neurological disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of functional neurological disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of functional neurological disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of functional neurological disorder by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with functional neurological disorder across the seven major markets?
What is the size of the functional neurological disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of functional neurological disorder?
What will be the growth rate of patients across the seven major markets?
Functional Neurological Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for functional neurological disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the functional neurological disorder market?
What are the key regulatory events related to the functional neurological disorder market?
What is the structure of clinical trial landscape by status related to the functional neurological disorder market?
What is the structure of clinical trial landscape by phase related to the functional neurological disorder market?
What is the structure of clinical trial landscape by route of administration related to the functional neurological disorder market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FUNCTIONAL NEUROLOGICAL DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FUNCTIONAL NEUROLOGICAL DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FUNCTIONAL NEUROLOGICAL DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 FUNCTIONAL NEUROLOGICAL DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FUNCTIONAL NEUROLOGICAL DISORDER - UNMET NEEDS
10 FUNCTIONAL NEUROLOGICAL DISORDER - KEY ENDPOINTS OF TREATMENT
11 FUNCTIONAL NEUROLOGICAL DISORDER - MARKETED PRODUCTS
11.1 List of Functional Neurological Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 FUNCTIONAL NEUROLOGICAL DISORDER - PIPELINE DRUGS
12.1 List of Functional Neurological Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. FUNCTIONAL NEUROLOGICAL DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FUNCTIONAL NEUROLOGICAL DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FUNCTIONAL NEUROLOGICAL DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Functional Neurological Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Functional Neurological Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Functional Neurological Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Functional Neurological Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Functional Neurological Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Functional Neurological Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Functional Neurological Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Functional Neurological Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Functional Neurological Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Functional Neurological Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Functional Neurological Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Functional Neurological Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Functional Neurological Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Functional Neurological Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Functional Neurological Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Functional Neurological Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Functional Neurological Disorder - Access and Reimbursement Overview
16 FUNCTIONAL NEUROLOGICAL DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FUNCTIONAL NEUROLOGICAL DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FUNCTIONAL NEUROLOGICAL DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FUNCTIONAL NEUROLOGICAL DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FUNCTIONAL NEUROLOGICAL DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FUNCTIONAL NEUROLOGICAL DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 FUNCTIONAL NEUROLOGICAL DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FUNCTIONAL NEUROLOGICAL DISORDER - UNMET NEEDS
10 FUNCTIONAL NEUROLOGICAL DISORDER - KEY ENDPOINTS OF TREATMENT
11 FUNCTIONAL NEUROLOGICAL DISORDER - MARKETED PRODUCTS
11.1 List of Functional Neurological Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 FUNCTIONAL NEUROLOGICAL DISORDER - PIPELINE DRUGS
12.1 List of Functional Neurological Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. FUNCTIONAL NEUROLOGICAL DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FUNCTIONAL NEUROLOGICAL DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FUNCTIONAL NEUROLOGICAL DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Functional Neurological Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Functional Neurological Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Functional Neurological Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Functional Neurological Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Functional Neurological Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Functional Neurological Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Functional Neurological Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Functional Neurological Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Functional Neurological Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Functional Neurological Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Functional Neurological Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Functional Neurological Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Functional Neurological Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Functional Neurological Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Functional Neurological Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Functional Neurological Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Functional Neurological Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Functional Neurological Disorder - Access and Reimbursement Overview
16 FUNCTIONAL NEUROLOGICAL DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FUNCTIONAL NEUROLOGICAL DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FUNCTIONAL NEUROLOGICAL DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
